Physician profile
William Black
NPI 1053722413
$7,669.34
in general payments reported to CMS, 2019-2025
34 companies · $2,443 in 2025
The $2,443 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $988 · 2021: $763 · 2022: $453 · 2023: $999 · 2024: $1,177 · 2025: $2,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,527 · Travel and Lodging: $2,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,527.30 |
| Travel and Lodging | $2,091.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $1,905.30 | 2025 | Indigo System |
| Abiomed | $1,782.00 | 2019-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $757.41 | 2019-2024 | Lifevest |
| Abbott Laboratories | $684.67 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $329.74 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $274.77 | 2019-2021 | |
| Pfizer INC. | $225.24 | 2020-2025 | |
| Stryker Corporation | $199.84 | 2025 | Flowtriever |
| Amgen INC. | $177.93 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $174.24 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.81 | 2019-2025 | Jardiance |
| Livanova USA, INC. | $130.36 | 2023 | Tandemlife |
| Astellas Pharma US INC | $101.79 | 2020 | |
| Inari Medical, INC. | $101.75 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Sanofi-Aventis U.S. LLC | $92.63 | 2022-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $74.97 | 2019-2023 | Xarelto |
| Medtronic, INC. | $63.91 | 2021-2024 | Symplicity G3 |
| Impulse Dynamics (USA) INC. | $59.91 | 2022-2023 | Optimizer |
| Merck Sharp & Dohme LLC | $37.18 | 2023 | Verquvo |
| Novo Nordisk INC | $34.96 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $34.05 | 2021-2024 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $30.79 | 2019 | |
| United Therapeutics Corporation | $24.63 | 2024 | Tyvaso |
| Cvrx, INC. | $24.58 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.23 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $22.46 | 2023 | Evkeeza |
| Lantheus Medical Imaging, INC. | $19.52 | 2019 | |
| Inspire Medical Systems, INC. | $18.96 | 2025 | Inspire |
| Terumo Medical Corporation | $18.58 | 2023 | Azur Cx Detachable, Angio-Seal |
| Scpharmaceuticals INC. | $16.62 | 2023 | |
| Genzyme Corporation | $15.71 | 2020 | |
| Teleflex LLC | $13.82 | 2022 | |
| Amarin Pharma, INC. | $13.75 | 2020 | |
| Alnylam Pharmaceuticals INC. | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.